Compare KORE & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KORE | SERA |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | 539 | N/A |
| Industry | Telecommunications Equipment | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 75.2M |
| IPO Year | N/A | 2021 |
| Metric | KORE | SERA |
|---|---|---|
| Price | $9.23 | $2.00 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 71.6K | 40.4K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | $8.96 | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $2.00 | $1.56 |
| 52 Week High | $9.79 | $3.95 |
| Indicator | KORE | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 54.72 |
| Support Level | $9.11 | $1.85 |
| Resistance Level | N/A | $2.03 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 18.25 | 75.34 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.